1 / 26

Platelet Disorders in Pregnancy

Platelet Disorders in Pregnancy. Joe Dietrick, CRNA, M.A. Have A Nice Day Anesthesia, LLC Chillicothe, MO. Overview. Hemostatic process Coagulation factors Coagulation tests Select platelet disorders Von Willebrand Disease Immune Thrombocytopenic Purpura

lani-wade
Download Presentation

Platelet Disorders in Pregnancy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Platelet Disorders in Pregnancy Joe Dietrick, CRNA, M.A. Have A Nice Day Anesthesia, LLC Chillicothe, MO

  2. Overview • Hemostatic process • Coagulation factors • Coagulation tests • Select platelet disorders • Von Willebrand Disease • Immune Thrombocytopenic Purpura • Thrombotic Thrombocytopenic Purpura

  3. General Hemostasis Hemostasis

  4. General hemostasis

  5. Hemostasis • 3 initial events • Vascular spasm • Platelet plug • Clot formation (coagulation) • Goal: Fibrinogen  fibrin: meshwork • Fibrous tissue formation • Solidified fibrin mesh • Fibrinolysis • Normally a good thing

  6. Platelet function1 • 2 forms • Circulate as Inactive: disc • Won’t interact with normal vascular endothelium • Activated: sphere with projections • 4 functions of Activated PLTs • Adherence to collagen • Activation & secretion of other mediators • Aggregation • Interaction w/other coag factors Lesoine, J. Electron Microscopy of Human Blood Cells. Retrieved 04/20/2009 from http://www.optics.rochester.edu/workgroups/cml/opt307/spr06/john/lesoineTEMSEM.htm

  7. Platelet function: Activation1 • Occurs on exposure to collagen • Clump PLTs together to seal leak • Activated PLTs release… • ADP: PLT aggregation & activation • Thromboxane A2: ↑ ADP & vasconstriction • ASA inhibits TXA2 production • Activated PLTs exposes PF3 • Phospholipid platform for coagulation

  8. Coagulating – backwards2 • Goal: Fibrinogen  fibrin • Fibrin meshwork on the PLT plug • Requires thrombin • Prothrombin  thrombin • Initiation: exposure of phospholipid platform • Extrinsic: release of thromboplastin • Intrinsic: exposure of PF3 & collagen Common Pathway Lesoine, J. Electron Microscopy of Human Blood Cells. Retrieved 04/20/2009 from http://www.optics.rochester.edu/workgroups/cml/opt307/spr06/john/lesoineTEMSEM.htm

  9. Coagulation factors2 • Circulate as procoagulants (except Ca++) • Vit. K dependent (warfarin-inhibited) • 2 (prothrombin), 7,9,10 • Synthesized in liver (except vWF) • Increased activity of Factors 7-10 in pregnancy: decreased response to warfarin • Ca++ enhances many steps

  10. Clinical assessment is most important Understand what is & isn’t tested Common tests/pathways are aPTT intrinsic & common, heparin PT extrinsic & common, warfarin INR Other tests include: ACT intrinsic & common, heparin BT platelet function & vascular function Quantitative studies: PLT Fibrinogen FDP/D-dimer Coagulation tests

  11. von Willebrand Disease3 • Most common inherited bleeding disorder • VIII:vW (aka vWF) – abnormal  vW Dz • VIII:C (aka VIII) – deficient  hemophilia • PLT adhesion to collagen: “intercellular glue” • Ristocetin enhances rxn • Increases ½ life of F-VIII • Basic testsSymptoms Normal PLT count Mild bleeding & bruising Abnormal BT May be unaware of dz Platelet interactions. Retrieved from UpToDate Online, 04/22/09: http://www.uptodateonline.com/online/content/images/hema_pix/Platelet_interactions.jpg

  12. von Willebrand Disease3 • Subtypes • 1 quantitative (not enough) 70% • 2 qualitative (don’t work well) 25% • 4 variants of Type 2 • 3severe, with  F-VIII as well • Mid-late pregnancy:  vWF 2-3x normal • Type 2 qualitative problems – still a problem • Most don’t require treatment • PP hemorrhage:  vWF in PP period

  13. vW Dz: what to do4 • Consult hematologist • Lab tests (diagnostic) • F-VIII – normalvWF-dependent survival • vWF:Ag < 30 IU/dl quantitative • vWF:RCo < 30 IU/dl qualitative • NIH (2008) • High-risk OB referral for delivery • F-VIII or vWF:RCo < 50, or • h/o severe bleeding

  14. vW Dz: treatment options4 • F-VIII & vWF:RCo > 50 • Before delivery or procedure • Maintain for 3-5 days PP • How to achieve • DDAVP • Factor replacement (Humate, Alphanate) • Cryo • FFP • PLT • Anti-fibrinolytics

  15. vW Dz: DDAVP4 • Desmopressin; synthetic vasopressin/ADH • Effectiveness tested before needed • 3 – 5 fold increase • Tachyphylaxis • 0.3 µg/kg IV Q 12° • Peak effect 30 – 90’, duration 6 – 12° • Max 20 µg, dilute in 50 ml, give over 30’ • Hyponatremia (+ fluids & oxytocin) • Limited data for use in pregnancy

  16. vW Dz: Factor replacement4 • vWF & F-VIII, but not interchangeable • Purified products  ↓ infectious risk • Humate-P • Indication:DDAVP contraindicated or inadequate • FDA approved prophylactic for surgery • Alphanate SD/HT • Indication:DDAVP contraindicated or inadequate • Not for Type 3 undergoing major surgery

  17. vW Dz: Other products4 • Cryoprecipitate • vWF & F-VIII – 1 pool (6 bags) • Strongly discouraged except in life-threatening circumstances • Fresh Frozen Plasma • Platelets • 10-15% of blood vWF • Adjunct, not primary tx • Anti-fibrinolytics

  18. vW Dz: Oh, anesthesia • Pre-delivery anesthetic evaluation • Avoid NSAIDs • Regional • NIH (2008): “If… • VWF:RCo and FVIII levels can be monitored and maintained above 50 IU/dL during labor and delivery, and • no other coagulation defects are present, then • regional anesthesia may be considered. Grade C, level IV.”4 • vWF & F-VIII > 50  regional can be considered3

  19. Nice case report11 • 15 y/o ♀Type 1 vWDz: : ACL reconstruction • Prevanesth: severe N/V with FentPCA (?) • Epidural post-op pain management • Preop assessment • vWF-a 48%,vWF-Rco 42%, F-VIII 48% • DDAVP trial 2 wks prior  successful • DOS: thorough consent • DDAVP, levels > 150% prior to procedure • DDAVP on POD 1 & 2

  20. ITP or ATP:Auto-Immune Thrombocytopenic Purpura6,7 • Lab • ↓ PLT < 100k (quantitative) • Nl – ↑ megakaryocytes (in bone marrow) • Diff Dx numerous • IgG-antibody mediated PLT destruction • Attack glycoproteins on PLT surface • Can cross placenta, esp 3rd trimester • Petechiae; young healthy females • Mortality 2° intracranial hemorrhage • Theoretically, may also occur in fetus

  21. ITP, ATP, we all…6,7 • RX: PLT > 50k (OB) PLT > 80k (Anesth) • Corticosteroids • IV immunoglobins • Splenectomy (2nd trim) • Rhogam (anti-D), [Rh+ pts only] • OB Concerns • Delivery method based on indications • Neuraxial anesthesia based on PLT count • Avoid NSAIDs

  22. Systematic Review (2009)10 • vWD • 74 techniques, all labor analgesia • No complications in 72 LEA, 2 combined • 64: Nl vWD indices • 10: treatment initiated prior to procedure • Tx: DDAVP or concentrates

  23. Systematic Review (2009)10 • ATP • 326 techniques, 324 OB; • No complications in 283 Epid, 41 spinal • 3 cases • Dx by  PLT after LEA: 20k, 18k, 26k! • PLT < 50k  tx (generally) • Cath removal • 1 of 14 articles tracked • Attempted to have >60k • But… 5/135 < 50k @ removal

  24. TTP:Thrombotic Thrombocytopenia Purpura6,7 • Disseminated PLT aggregation •  vWF cleaving protease • 5 features • ↓ PLT  Hemolytic anemia • Renal failure  Fever  Neurologic signs • Tx: Plasmapheresis, steroids, prostacyclin • PLT transfusions historically avoided • 2009: don’t withhold if surgically/procedure indicated • Neuraxial anesthesia contraindicated6

  25. And all of this means… • vW Dz • Lab: factors > 50 • 1° treatment: DDAVP, ideally pre-tested • Type 3 won’t respond • ITP is quantitative deficiency • May be on steroids • May require splenectomy while pregnant • TTP is deadly • Uncomplicated PLT ≥ 80k safe, Epid/SAB9

  26. References • Petrovitch, C. (1992). Perioperative Evaluation of Coagulation. ASA Refresher Courses in Anesthesiology, 20: 169-189. • Stoelting, R. (1991). Pharmacology & Physiology in Anesthetic Practice. Philadelphia: J.B. Lippincott Co. • Treatment of von Willebrand’s Disease. Retrieved from UpToDate Online 04/22/09: http://uptodateonline.com/online/content/topic.do?topicKey=coagulat/9525. • The Diagnosis, Evaluation, & Management of von Willebrand Disease (2008). National Institutes of Health, Pub 08-5832. • Butwick, A. & Carvalho, B. (2007). Neuraxial anesthesia for cesarean delivery in a parturient with type 1 von Willebrand disease and scoliosis. Journal of Clinical Anesthesia 19: 230–233 • Sharma, S. & Lechner, R. (2004). Hematologic & Coagulation Disorders. In Chestnut, D. (Ed), Obstetric Anesthesia, Principles & Practice, 3rd Ed ( Pg 764- 779). • Strong, J. (2003). Bleeding disorders in pregnancy. Current Obstetrics & Gynaecology, 13:1-6. • Swisher, K. et al (2009). Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. TRANSFUSION, 49:873-887. • Joost, J et al. (2010). The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals. British Journal of Haematology, 148, 15–25. • Choi, S & Brull, R (2009). Neuraxial Techniques in Obstetric & Non-obstetric Patients with Common Bleeding Disorders. International Anesthesia Research Society, 109(2):648-660. • Hara, K et al (2009). Considerations for epidural anesthesia in a patient with type 1 von Willebrand disease. Journal of Anesthesia, 23:597-600.

More Related